Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity

Author:

Govender Preshendren1ORCID,Müller Rudolf1,Singh Kawaljit1,Reddy Virsinha1,Eyermann Charles J.1,Fienberg Stephen1,Ghorpade Sandeep R.1ORCID,Koekemoer Lizbé2,Myrick Alissa2,Schnappinger Dirk3,Engelhart Curtis3,Meshanni Jaclynn3,Byl Jo Ann W.4,Osheroff Neil456ORCID,Singh Vinayak12ORCID,Chibale Kelly12ORCID,Basarab Gregory S.17ORCID

Affiliation:

1. Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

2. Drug Discovery and Development Centre (H3D) South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

3. Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States

4. Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

5. Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

6. VA Tennessee Valley Healthcare System, Nashville, Tennessee 37212, United States

7. Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, 7935, South Africa

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

University of Cape Town

National Institute of General Medical Sciences

Department of Science and Innovation, South Africa

South African Medical Research Council

Biomedical Laboratory Research and Development, U.S. Department of Veterans Affairs

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Reference53 articles.

1. Tuberculosis: Key facts. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (accessed February 14, 2022).

2. New TB drugs. https://tbfacts.org/new-tb-drugs/ (accessed February 14, 2022).

3. Two Decades of TB Drug Discovery Efforts—What Have We Learned?

4. Strategies to Combat Multi-Drug Resistance in Tuberculosis

5. Mechanism of Quinolone Action and Resistance

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3